HSV 2 IgG Inhibition, IA: Positive or Negative, What It Means

If your report has a line reading HSV 2 IgG Inhibition, IA, you are looking at something most people never see, and almost nothing online explains it. Here is the short version: this is not your herpes test. It is the test that checks your herpes test.

Your HSV-2 IgG screening result came back positive with an index somewhere between 1.10 and 6.00 — the range where the screening assay is known to produce false positives. So the lab ran a second, different method on the same sample, to find out whether the first result was real.

The one idea that explains this whole page: the lab took your sample and tried to make the positive disappear. A positive inhibition result means it disappeared — which is what happens only when the antibodies genuinely target HSV-2. Counterintuitively, positive here means the first test was right, and negative here means the first test was wrong.

Clinical Takeaway. Positive inhibition confirms your screening positive was genuine. Negative inhibition means it most likely was not. Neither result tells you when you were infected, the precise site, or whether you are contagious today — and the percentage behind the result describes how much the antigen removed from the signal — not how much virus you carry, and not how you are.

At a glance

• What it is: a confirmatory test, run only on samples that already screened positive for HSV-2 IgG.
• Sample: serum.
• When it runs: automatically, when the HSV-2 IgG screening index is 1.10–6.00.
• Reported as: Positive, Negative, or "could not be determined."
• Underlying measure: percent inhibition — above 60% is positive.
• Where it runs: Quest Diagnostics only. It is a laboratory-developed test, not a commercial kit.
• What positive means: your screening positive was genuine.
• What negative means: your screening positive was probably false.
• What it cannot tell you: when infection occurred, the precise anatomical site, whether you are shedding now, or whether symptoms will develop.

Why your sample was sent for this test

The HSV-2 IgG screening test looks for antibodies against glycoprotein G-2, a protein found only on HSV-2. Anything above an index of 1.09 is reported positive.

The problem is that the assay's false positives are not scattered evenly. They pile up just above the cutoff. So an index of 1.3 is simultaneously a positive result and the least reliable kind of positive result the assay produces — which is an uncomfortable thing to hand someone as a herpes diagnosis.

How unreliable? The CDC cites a study of HerpeSelect, the most widely used HSV-2 antibody screen, reporting an overall specificity of 57.4%, falling to 39.8% at index values of 1.1–2.9. Its conclusion is blunt: because commercially available type-specific antibody tests have poor specificity, particularly below an index of 3.0, a confirmatory test using a second method should be performed before the result is interpreted at all.

Quest reflexes further than that ceiling, all the way to 6.00. When Quest's own laboratory compared screen-positive samples against the inhibition assay, 39% of the false positives on the Liaison platform had indices above 3.50 — evidence that a lower cutoff leaves false positives unconfirmed.

If your index came back above 6.00, the inhibition test was not run, because Quest's reflex protocol does not extend past 6.00. That is a boundary in a testing workflow, not a finding that results above 6.00 need no interpretation. Treat it as you would any other positive: a result to take to your clinician.

How the test actually works

Your serum is divided into three portions.

One is left alone. It is run on a HerpeSelect HSV-2 IgG ELISA, and it establishes your baseline signal — how strongly your antibodies bind the gG2 antigen on the plate.

The second is pre-incubated with HSV-2 lysate: ground-up material from HSV-2-infected cells. If your antibodies are genuinely HSV-2-specific, they will bind that lysate in the tube and never make it to the plate. The signal drops.

The third is pre-incubated with HSV-1 lysate, as a control.

The lab compares the treated signals to the baseline and calculates how much of the signal the HSV-2 lysate removed. That percentage is the inhibition. Above 60%, your antibodies were genuinely HSV-2-specific and the result is reported positive. Below 60%, the assay does not demonstrate HSV-2-specific IgG, and the result is reported negative.

Reading your result

"The inhibition result could not be determined"

Your report may carry a message roughly like this: the screening assay was repeated on a different platform as part of the inhibition test, the result was negative, and so the inhibition result could not be determined.

Here is what happened. Your sample was screened on one instrument and confirmed on a different one — a Diasorin Liaison XL for the screen, a HerpeSelect ELISA for the inhibition. The inhibition calculation needs a measurable baseline on the second assay. Sometimes there isn't one: the sample was positive on the first platform and does not register on the second. Without a baseline, there is no percentage to calculate, and the lab cannot report a verdict either way.

This is more common in samples with low screening indices, and Quest's report language notes that it may itself point toward the original result being a false positive. But it is not a negative result, and it should not be read as one.

The two ways forward are a fresh sample in 2–3 weeks, or a Herpes Western blot, which is available directly through the University of Washington.

Two people, the same negative inhibition

Two people open their reports. Both read: HSV 2 IgG Inhibition, IA — Negative.

Person A had a routine STI panel done as part of a physical. No symptoms, no known exposures, no reason to suspect anything. For her, this result closes the question. A screening test misfired, the confirmation caught it, and the system worked exactly as designed.

Person B tested because of a possible exposure five weeks ago. For him, the same word means much less. Antibodies take time to develop — typically around three weeks after symptoms begin, but some people take six months or longer, and the confirmatory assay cannot find antibodies that have not been made yet. A negative inhibition result cannot distinguish "you don't have HSV-2" from "you have it and your immune system hasn't caught up." He needs a repeat sample around 12 weeks after the exposure.

Same word. One of them is finished; the other is halfway through.

What this test cannot tell you

It cannot tell you when you were infected. Antibodies persist for life and carry no timestamp.

It cannot identify the precise anatomical site. Confirmed HSV-2 antibodies generally imply anogenital infection, because HSV-2 is almost always sexually acquired — but a blood test cannot locate the virus, show where shedding is happening, or tell you whether any particular past symptom was caused by HSV-2.

It cannot tell you whether you are contagious right now. That is a question about viral shedding, and it needs a swab, not a blood test.

It cannot tell you who you got it from, or when a partner acquired theirs.

It cannot tell you whether you will ever have symptoms. Many people with confirmed HSV-2 antibodies never do.

It cannot fully rule out recent infection. A negative result inside the seroconversion window means very little.

Inhibition or Western blot?

The Herpes Western blot, performed at the University of Washington, has historically been called the gold standard, and people who receive a positive inhibition result sometimes ask whether they should get one to be sure.

A second confirmatory test is not automatically needed after a positive inhibition result, and the reason is counterintuitive. Quest describes the HSV-2 IgG inhibition assay as more sensitive than the Herpes Western Blot during early infection. Antibodies may become detectable on the HerpeSelect-based inhibition method around three weeks after symptoms begin, compared with roughly ten weeks by Western blot. During that interval, the Western blot may give a false-negative result while a true-positive specimen may already be positive by inhibition.

The CDC recommends confirming low-positive HSV-2 EIA results with a second method, and specifically names Biokit or Western blot. Quest uses its HSV-2 inhibition assay as the confirmatory step in its own reflex workflow.

The Western blot's real value is as an independent method when the inhibition assay could not produce a result at all, or when the clinical picture and the serology genuinely disagree.

Both tests are laboratory-developed tests rather than commercial kits, and neither is available everywhere. The inhibition assay is performed only at Quest. If this line is on your report, your sample went to Quest — even if your blood was drawn somewhere else.

Common interpretation mistakes

Reading "Inhibition: Positive" as a second diagnosis. It is not a new finding. It is a verdict on an existing one.

Reading "Inhibition: Negative" as "the virus is being inhibited." Nothing in your body is being inhibited. The inhibition happened in a tube, to your sample, on purpose.

Assuming the percentage measures how much virus or how much antibody you have. It describes how much the antigen removed from the signal — not how much virus you carry, and not how you are.

Assuming a higher screening index makes a false positive unlikely. Quest's own data found 39% of false positives on their screening platform had indices above 3.50.

Assuming a negative inhibition result rules HSV-2 out. Inside the seroconversion window, it does not.

Assuming the Western blot is automatically the better test. Quest describes it as less sensitive than the inhibition assay during early infection, when the Western blot may still give a false-negative result.

Questions your doctor may ask

When was the possible exposure? This is the question that determines whether a negative result means anything.

Have you ever had genital lesions, sores, or unexplained irritation — even once, even years ago, even if you assumed it was something else?

Has a partner ever been diagnosed with genital herpes?

Have you ever had a swab or PCR taken from a lesion? A positive swab settles the question far more directly than any antibody test.

Why was this test ordered? Neither the CDC nor the USPSTF recommends routine HSV screening in people without symptoms, precisely because of the false-positive problem this test exists to clean up.

Read together with

HSV 2 IgG, Type Spec — the screening result that sent your sample here. The index value on that line is what determined whether this test was run at all.

HSV 1 IgG, Type Spec — usually run alongside. A positive HSV-1 result is extremely common and, on its own, unremarkable.

Clinical pearls

The reflex window is 1.10–6.00, wider than the CDC's confirmation threshold of 3.0, because Quest's own review found false positives living above 3.50.

The screen and the confirmation run on different assays — Liaison XL and HerpeSelect. That mismatch is the source of the "could not be determined" outcome, and it is a design consequence, not a lab error.

If your report has an inhibition line, your sample was at Quest. ARUP, among others, refers this test out to them.

The test is not performed on equivocal or negative screening results — only on positives.

In one sentence

A Quest-only confirmatory assay that decides whether a low-positive HSV-2 antibody screen was true or false.

The bottom line

A positive inhibition result confirms that you have HSV-2 antibodies, which means past exposure and lifelong antibody persistence — and says nothing about severity, timing, the precise anatomical site, or whether you will ever have symptoms. A negative inhibition result means the screening test most likely misfired, which is common in the low-positive range this test exists to police. Either way, the percentage describes how much the antigen removed from the signal — not how much virus you carry, and not how you are.